Guardant Health Stock Price, News & Analysis

Guardant Health (Nasdaq: GH) announced Medicare coverage expansion for its Guardant Reveal test through Palmetto GBA. The coverage now includes surveillance testing for colorectal cancer (CRC) patients following curative intent therapy, expanding from the previous early post-surgical setting coverage.

The Guardant Reveal, running on the Smart Liquid Biopsy platform, is a blood-based test that uses epigenomic analysis to detect circulating tumor DNA (ctDNA) for minimal residual disease (MRD) monitoring. This tissue-free approach addresses the needs of cancer patients without available tissue specimens or those for whom tissue collection is challenging.

Of the 18 million cancer patients in the U.S. who could benefit from MRD testing, less than 3% currently receive it. Over 12 million cancer patients are more than five years post-surgery, making tissue specimen collection difficult, and over three million patients have no tumor tissue available.

Guardant Health (GH) and ConcertAI have announced a collaboration to create the first multi-modal real-world data solution that integrates comprehensive patient electronic medical records with genomic and epigenomic tumor profiling information across cancer care. The partnership combines ConcertAI's database of 5.5M clinical records with Guardant's profiling data across 60+ tumor types.

The integrated platform will provide biopharmaceutical companies access to extensive data including methylation data from Guardant Infinity smart liquid biopsy platform, helping researchers better understand disease biology, identify drivers of tumor evolution, and study resistance mechanisms. The solution covers the entire cancer care spectrum, from monitoring residual disease in early-stage cancer to treatment selection in advanced cases.

This collaboration aims to accelerate cancer therapy research and development by providing unprecedented insights into patient cancer journeys and tumor interactions. Financial terms of the agreement were not disclosed.

Viz.ai and Guardant Health (GH) announced a proposed collaboration to improve lung cancer care through the integration of AI and genomic insights. The partnership aims to address the critical issue that approximately 40% of lung cancer patients do not receive guideline-directed medical therapy.

The collaboration will focus on facilitating timely biomarker testing using Guardant360® CDx liquid biopsy, accelerating precision diagnosis and treatment selection. Viz.ai's platform, currently implemented in 1,700 hospitals, uses machine learning to analyze imaging data, EHR, and other tests to provide real-time insights and automated assessments.

This initiative aims to tackle delays in diagnosis, testing, and treatment that can lead to cancer progression and higher mortality rates. The partnership combines Viz.ai's AI-powered disease detection capabilities with Guardant Health's precision oncology expertise to streamline the patient journey and improve outcomes.

Guardant Health (GH) reported strong preliminary Q4 and full-year 2024 results, with total revenue reaching approximately $200 million in Q4 (29% increase) and $737 million for the full year (31% increase). The company saw significant growth in test volumes, with 57,300 oncology clinical tests (24% increase) and 11,050 biopharma tests (16% increase) in Q4.

The Shield screening program reported approximately 6,400 tests with revenue of $4 million. For the full year, the company conducted 206,700 oncology clinical tests and 40,500 biopharma tests, showing increases of 20% and 35% respectively. Free cash flow was negative $84 million in Q4 and negative $275 million for 2024. The company maintained a strong cash position of $944 million as of December 31, 2024.

Guardant Health (Nasdaq: GH) announced its Shield™ multi-cancer detection (MCD) test has been selected by the National Cancer Institute (NCI) for inclusion in the Vanguard study. The selection was based on the platform's strong performance in detecting various cancer types and predicting cancer tissue origin.

The Vanguard study is a four-year pilot initiative by the NCI's Cancer Screening Research Network (CSRN) that will enroll up to 24,000 people to inform the design of a larger randomized controlled trial evaluating MCD tests for cancer screening. Guardant Health was chosen as one of only two participants after evaluation of multiple companies.

The study will assess the Shield platform's performance in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric cancers. Results from the NCI verification study are expected in early 2025.

Guardant Health (Nasdaq: GH), a leading precision oncology company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management team will deliver a presentation followed by a Q&A session on Monday, January 13, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time.

Interested investors and stakeholders can access both live and archived webcasts of the sessions through the 'Investors' section of Guardant Health's official website at www.guardanthealth.com.

Guardant Health (Nasdaq: GH) and Meaningful Insights Biotech Analytics (MiBA) have announced a strategic partnership to enhance precision oncology through biomarker testing and data analytics. The collaboration combines MiBA's AI technologies and oncology data with Guardant's expertise in tumor profiling and circulating tumor DNA monitoring.

The partnership aims to transform cancer care by implementing personalized, data-driven approaches that improve access to innovative treatments. The initiative will provide healthcare stakeholders with knowledge about biomarker testing, cancer recurrence monitoring tools, and data insights throughout the care continuum, ultimately improving cancer patient care standards.

COTA and Guardant Health (Nasdaq: GH) announced a partnership to combine their oncology data resources for advancing precision cancer therapy development. The collaboration merges COTA's research-grade EHR data from academic and community care centers with Guardant's clinicogenomic testing data.

This partnership aims to help researchers better understand correlations between molecular biomarkers, treatments, and clinical outcomes. The combined dataset and AI analytics will support more efficient drug development, particularly given that 97% of cancer clinical trials fail and development can take up to fifteen years.

The collaboration expands COTA's data breadth into solid tumors, focusing on lung, breast, and colorectal cancers. Guardant's data covers all disease stages, from initial tumor profiling to therapy monitoring, while COTA's data tracks complete cancer care journeys.

Guardant Health (Nasdaq: GH) announced a collaboration with Boehringer Ingelheim to develop the Guardant360® CDx liquid biopsy as a companion diagnostic for zongertinib, an investigational treatment for non-small cell lung cancer (NSCLC). The blood test will identify NSCLC patients with HER2 mutations who may benefit from zongertinib treatment.

According to Guardant Health's chairman, approximately 40,000 people worldwide are diagnosed annually with NSCLC with HER2 mutations, who often respond poorly to standard treatments. The Guardant360 CDx is already FDA-approved for comprehensive liquid biopsy in advanced solid tumors and serves as a companion diagnostic for multiple NSCLC targeted therapies and breast cancer therapy targeting ESR1 mutations.